News & Events
Tuesday, June 29, 2010
Soligenix to Present at the OneMedForum Conference
on Wednesday, June 30 at 2PM EDT
[read more]Friday, June 25, 2010
Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
[read more]Wednesday, June 16, 2010
Soligenix Announces Private Equity Financing of $5.16 Million with its Partner Sigma-Tau and other Institutional Investors
[read more]Thursday, June 03, 2010
Soligenix Announces Grant of European Patent for the Treatment of GVHD and Leukemia with Oral Beclomethasone Dipropionate
[read more]Wednesday, May 19, 2010
Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
[read more]Monday, May 17, 2010
Soligenix Reports First Quarter 2010 Financial Results and
Reviews Accomplishments
[read more]Wednesday, May 12, 2010
Soligenix Announces Completion of Patient Enrollment
in Phase 2 Acute GVHD Prevention Clinical Trial
[read more]Monday, May 10, 2010
Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
[read more]Thursday, April 01, 2010
Soligenix Reports Year-End 2009 Financial Results and
Reviews Accomplishments
[read more]Wednesday, February 17, 2010
Soligenix Announces Issuance of Hong Kong Patent for its LPM™ Oral Drug Delivery Technology
[read more]Wednesday, February 03, 2010
Soligenix to Present at 12th Annual BIO CEO & Investor Conference
[read more]Tuesday, February 02, 2010
Soligenix Announces Publication of Positive Stability Results with RiVax™, its Vaccine Against Ricin Toxin
Preclinical Data Demonstrate the Potential for Long-term Stability of RiVax™ [read more]
